tetano
Editor, Senior Moderator
Int J Immunopathol Pharmacol
. Jan-Dec 2021;35:20587384211063976.
doi: 10.1177/20587384211063976.
Systemic corticosteroids for management of COVID-19: Saving lives or causing harm?
Alireza FakhriRavari[SUP] 1 [/SUP], Stephanie Jin[SUP] 1 [/SUP], Farrnam H Kachouei[SUP] 2 [/SUP], Diana Le[SUP] 1 [/SUP], Mireya Lopez[SUP] 1 [/SUP]
Affiliations
Abstract
The underlying cause of many complications associated with severe COVID-19 is attributed to the inflammatory cytokine storm that leads to acute respiratory distress syndrome (ARDS), which appears to be the leading cause of death in COVID-19. Systemic corticosteroids have anti-inflammatory activity through repression of pro-inflammatory genes and inhibition of inflammatory cytokines, which makes them a potential medical intervention to diminish the upregulated inflammatory response. Early in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, the role of corticosteroids was unclear. Corticosteroid use in other indications such as ARDS and septic shock has proven benefit while its use in other respiratory viral pneumonias is associated with reduced viral clearance and increased secondary infections. This review article evaluates the benefits and harms of systemic corticosteroids in patients with COVID-19 to assist clinicians in improving patient outcomes, including patient safety. Dexamethasone up to 10 days is the preferred regimen to reduce mortality risk in COVID-19 patients requiring oxygen support, mechanical ventilation, or extracorporeal membrane oxygenation. If dexamethasone is unavailable, other corticosteroids can be substituted at equivalent doses. Higher doses of corticosteroids may be beneficial in patients who develop ARDS. Corticosteroids should be avoided early in the disease course when patients do not require oxygen support because of potential harms.
Keywords: COVID-19; Corticosteroids; SARS-CoV-2; dexamethasone; hydrocortisone;
. Jan-Dec 2021;35:20587384211063976.
doi: 10.1177/20587384211063976.
Systemic corticosteroids for management of COVID-19: Saving lives or causing harm?
Alireza FakhriRavari[SUP] 1 [/SUP], Stephanie Jin[SUP] 1 [/SUP], Farrnam H Kachouei[SUP] 2 [/SUP], Diana Le[SUP] 1 [/SUP], Mireya Lopez[SUP] 1 [/SUP]
Affiliations
- PMID: 34923856
- DOI: 10.1177/20587384211063976
Abstract
The underlying cause of many complications associated with severe COVID-19 is attributed to the inflammatory cytokine storm that leads to acute respiratory distress syndrome (ARDS), which appears to be the leading cause of death in COVID-19. Systemic corticosteroids have anti-inflammatory activity through repression of pro-inflammatory genes and inhibition of inflammatory cytokines, which makes them a potential medical intervention to diminish the upregulated inflammatory response. Early in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, the role of corticosteroids was unclear. Corticosteroid use in other indications such as ARDS and septic shock has proven benefit while its use in other respiratory viral pneumonias is associated with reduced viral clearance and increased secondary infections. This review article evaluates the benefits and harms of systemic corticosteroids in patients with COVID-19 to assist clinicians in improving patient outcomes, including patient safety. Dexamethasone up to 10 days is the preferred regimen to reduce mortality risk in COVID-19 patients requiring oxygen support, mechanical ventilation, or extracorporeal membrane oxygenation. If dexamethasone is unavailable, other corticosteroids can be substituted at equivalent doses. Higher doses of corticosteroids may be beneficial in patients who develop ARDS. Corticosteroids should be avoided early in the disease course when patients do not require oxygen support because of potential harms.
Keywords: COVID-19; Corticosteroids; SARS-CoV-2; dexamethasone; hydrocortisone;
